Introduction: Complement activation at the neuromuscular junction is a primary cause of acetylcholine receptor loss and failure of neuromuscular transmission in myasthenia gravis (MG). Eculizumab, a humanized monoclonal antibody, blocks the formation of terminal complement complex by specifically preventing the enzymatic cleavage of complement 5 (C5).
Methods: This study was a randomized, double-blind, placebo-controlled, crossover trial involving 14 patients with severe, refractory generalized MG (gMG).
Results: Six of 7 patients treated with eculizumab for 16 weeks (86%) achieved the primary endpoint of a 3-point reduction in the quantitative myasthenia gravis (QMG) score. Examining both treatment periods, the overall change in mean QMG total score was significantly different between eculizumab and placebo (P = 0.0144). After assessing data obtained from all visits, the overall change in mean QMG total score from baseline was found to be significantly different between eculizumab and placebo (P < 0.0001). Eculizumab was well tolerated.
Conclusion: The data suggest that eculizumab may have a role in treating severe, refractory MG.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mus.23839 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interleukin-27 and Autoimmune Disorders: A Compressive Review of Immunological Functions.
Biomolecules
November 2024
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.
Autoimmune disorders (ADs) pose significant health and economic burdens globally, characterized by the body's immune system mistakenly attacking its own tissues. While the precise mechanisms driving their development remain elusive, a combination of genetic predisposition(s) and environmental triggers is implicated. Interleukin-27 (IL-27), among numerous cytokines involved, has emerged as a key regulator, exhibiting dual roles in immune modulation.
View Article and Find Full Text PDFCutoffs on severity metrics for minimal manifestations or better status in patients with generalized myasthenia gravis.
Front Immunol
January 2025
Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.
International consensus guidance and Japanese clinical guidelines for myasthenia gravis (MG) recommend achieving minimal manifestations or better status (MM-or-better) as the severity component of the treatment goal. However, the subjective nature of determining MM can result in ambiguity regarding this category in clinical practice and clinical trials. This study analyzed severity metrics in a large number of MG patients to propose criteria for MM-or-better.
View Article and Find Full Text PDFPredictive modeling and interpretative analysis of risks of instability in patients with Myasthenia Gravis requiring intensive care unit admission.
Heliyon
December 2024
Department of Neurology, Taipei Medical University - Shuang Ho Hospital, New Taipei City, 235, Taiwan.
Objective: Myasthenia gravis (MG), a low-prevalence autoimmune disorder characterized by clinical heterogeneity and unpredictable disease fluctuations, presents significant risks of acute exacerbations requiring intensive care. These crises contribute substantially to patient morbidity and mortality. This study aimed to develop and validate machine-learning models for predicting intensive care unit (ICU) admission risk among patients with MG-related disease instability.
View Article and Find Full Text PDFPD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024.
Hum Vaccin Immunother
December 2025
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Programmed cell death-1 (PD-1) inhibitors and programmed cell death ligand 1 (PD-L1) inhibitors are considered effective alternatives for the primary treatment of recurrent metastatic cancers. However, they can induce various adverse events affecting multiple organ systems, potentially diminishing patients' quality of life, and even leading to treatment interruptions. Adverse events related to PD-1/PD-L1 inhibitors differ from those associated with CTLA-4 inhibitors and are more commonly observed in the treatment of solid tumors.
View Article and Find Full Text PDFSirt6, Deubiquitinated and Stabilised by USP9X, Takes Essential Actions on the Pathogenesis of Experimental Autoimmune Myasthenia Gravis by Regulating CD4 T Cells.
Clin Exp Pharmacol Physiol
February 2025
Department of Thoracic Surgery, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China.
Myasthenia gravis (MG) presents with symptoms that significantly affect patients' daily lives. Long-term MG therapies may lead to substantial side effects, predominantly due to prolonged immune suppression. Sirt6, which plays a vital role in maintaining cellular homeostasis and is recognised for its involvement in cytokine production in immune cells, has not yet been explored in relation to MG.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!